Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 18,005 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $27.83, for a total transaction of $501,079.15. Following the transaction, the chief financial officer directly owned 270,046 shares of the company’s stock, valued at approximately $7,515,380.18. This trade represents a 6.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.98, for a total transaction of $79,420.50.
• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total transaction of $219,088.09.
• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total transaction of $275,092.78.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded up $2.19 during trading on Monday, reaching $31.01. 69,081,711 shares of the company’s stock traded hands, compared to its average volume of 34,160,496. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a 50-day simple moving average of $19.72 and a 200-day simple moving average of $32.11. The firm has a market cap of $7.07 billion, a PE ratio of 60.80, a P/E/G ratio of 2.74 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.Hims & Hers Health’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.11 EPS. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.61 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research report on Tuesday, March 10th. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. TD Cowen decreased their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, March 27th. Morgan Stanley decreased their target price on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Finally, Bank of America lifted their price target on Hims & Hers Health from $21.00 to $25.00 and gave the stock a “neutral” rating in a research note on Thursday. Three equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $31.86.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Quent Capital LLC acquired a new position in Hims & Hers Health during the third quarter worth about $28,000. Flagship Harbor Advisors LLC acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $28,000. Binnacle Investments Inc purchased a new position in Hims & Hers Health in the 3rd quarter worth approximately $28,000. Bogart Wealth LLC boosted its holdings in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health during the 1st quarter worth approximately $30,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.